Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson. AtaiBeckley’s lead candidate is BPL-003, a fast-acting intranasal formulation of the psychedelic substance 5-MeO-DMT. The substance, which is found in some plants and animals, stimulates the serotonin system that regulates mood. A phase 2b trial linked BPL-003 to statistically significant improve

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with the help of a $315 million series D . The round was led by Ally Bridge Group and Alpha Wave, with returning support from the investment arms of Sanofi and Eli Lilly and new funders like Bain Capital Life Sciences. The series D has its origins at January’s J.P. Morgan Healthcare Conference, where radiotherapy wa

Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest’s CDMO customers and partners July 15, 2026 - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) g

Spero Therapeutics is putting over $1 billion on the line in exchange for rights to develop SP001, an anti-CD40L antibody, for IgG4-related disease. A Phase 2 study is planned for the second quarter of 2027. Spero Therapeutics has licensed an investigational autoimmune disease therapy from China-based Innovent Biologics. The total deal value could reach up to $1.1 billion, according to a Tuesday morning news release. This sum includes Spero’s upfront commitment, as well as R&D, regulatory and

July 14, 2026 -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer's disease. The US launch is planned for late August 2026. Leqembi Iqlik is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home d

GSK reported interim findings Monday for PD-1 inhibitor Jemperli (dostarlimab), which met its primary endpoint in a registrational trial involving patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer. The UK pharma is planning to share the data with global regulators, including in the US, where the antibody may benefit from a speedy review. The single-arm Phase II AZUR-1 trial enrolled 154 patients to receive nine cycle

The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA July 14, 2026 -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, t

July 14, 2026-- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso. The study is be

A year after emerging from stealth, Draig Therapeutics has closed an oversubscribed $65-million series B that will go toward accelerating its neuropsychiatric drug pipeline, with depression treatment DT-101 leading the charge. DT-101 is a positive allosteric modulator of the AMPA receptor that is being evaluated for major depressive disorder (MDD). The drug is currently being studied in two Phase II trials: a global study assessing DT-101 as monotherapy and a US study testing it in the adjunct

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. July 13, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise The